References
- 1. Somberg JS, Molnar J. Usefulness of QT dispersion as an electrocardiographically derived index. Am J Cardiol. 2002;89:291-294. doi: 10.1016/s0002-9149(01)02230-5.10.1016/S0002-9149(01)02230-5
- 2. Yu Z, Chen Z, Wu Y, et al. Electrocardiographic parameters effectively predict ventricular tachycardia/fibrillation in acute phase and abnormal cardiac function in chronic phase of ST-segment elevation myocardial infarction. J Cardiovasc Electrophysiol. 2018;29:756-766. doi: 10.1111/jce.13453.10.1111/jce.13453
- 3. Malik M, Batchvarov VN. Measurement, interpretation and clinical potential of QT dispersion. J Am Coll Cardiol. 2000;36:1749-1766. doi: 10.1016/s0735-1097(00)00962-1.10.1016/S0735-1097(00)00962-1
- 4. Kanbay M, Solak Y, Dogan E, et al. Uric Acid in Hypertension and Renal Disease: The Chicken or the Egg. Blood Purif. 2010;30:288-295. doi: 10.1159/000321074.10.1159/000321074
- 5. Ahmadnezhad M, Arefhosseini SR, Parizadeh MR, et al. Association between serum uric acid, high sensitive C-reactive protein and pro-oxidant-antioxidant balance in patients with metabolic syndrome. Biofactors. 2018;44:263-271. doi: 10.1002/biof.1424.10.1002/biof.1424
- 6. Grayson PC, Kim SY, LaValley M, et al. Hyperuricemia and incident hypertension: A systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2011;63:102-110. doi: 10.1002/acr.20344.10.1002/acr.20344
- 7. Kim SY, Guevara JP, Kim KM, et al. Hyperuricemia and risk of stroke: A systematic review and meta-analysis. Arthritis and Rheumatism. 2009;61:885-892. doi: 10.1002/art.24612.10.1002/art.24612
- 8. Kim SY, Guevara JP, Kim KM, et al. Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2010;62:170-180. doi: 10.1002/acr.20065.10.1002/acr.20065
- 9. Kodama S, Saito K, Yachi Y, et al. Association between serum uric acid and development of type 2 diabetes. Diabetes Care. 2009;32:1737-1742. doi: 10.2337/dc09-0288.10.2337/dc09-0288
- 10. Zhang JX, Lin X, Xu J, et al. Hyperuricemia Inhibition Protects SD Rats Against Fructose-Induced Obesity Hypertension Via Modulation of Inflammation and Renin-Angiotensin System in Adipose Tissue. Exp Clin Endocrinol Diabetes. 2021;129:314-321. doi: 10.1055/a-1023-6710.10.1055/a-1023-6710
- 11. Krishnan E, Sokolove J. Uric acid in heart disease: a new C-reactive protein? Curr Opin Rheumatol. 2011;23:174-177. doi: 10.1097/BOR.0b013e3283432dd3.10.1097/BOR.0b013e3283432dd3
- 12. Straus SM, Kors JA, De Bruin ML, et al. Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. J Am Coll Cardiol. 2006;47:362-367. doi: 10.1016/j.jacc.2005.08.067.10.1016/j.jacc.2005.08.067
- 13. Ryerson LM, Giuffre RM. QT intervals in metabolic dilated cardiomyopathy. Can J Cardiol. 2006;22:217-220. doi: 10.1016/s0828-282x(06)70899-6.10.1016/S0828-282X(06)70899-6
- 14. Elming H, Holm E, Jun L, et al. The prognostic value of the QT interval and QT interval dispersion in all-cause and cardiac mortality and morbidity in a population of Danish citizens. Eur Heart J. 1998;19:1391-1400. doi: 10.1053/euhj.1998.1094.10.1053/euhj.1998.1094
- 15. Cuddy TE, Halli PS, Tate RB. QT dispersion and heart rate predict the risk of sudden unexpected cardiac death in men: the Manitoba Follow-Up Study. Prev Cardiol. 2009;12:27-33. doi: 10.1111/j.1751-7141.2008.00016.x.10.1111/j.1751-7141.2008.00016.x
- 16. Bazoukis G, Yeung C, Wui Hang Ho R, et al. Association of QT dispersion with mortality and arrhythmic events-A meta-analysis of observational studies. J Arrhythm. 2019;36:105-115. doi: 10.1002/joa3.12253.10.1002/joa3.12253
- 17. Brooksby P, Robinson PJ, Segal R, et al. Effects of losartan and captopril on QT dispersion in elderly patients with heart failure. ELITE study group. Lancet. 1999;534:395-396. doi: 10.1016/s0140-6736(99)01354-9.10.1016/S0140-6736(99)01354-9
- 18. Uchiyama K, Hayashi K, Fujino N, et al. Impact of QT variables on clinical outcome of genotyped hypertrophic cardiomyopathy. Ann Noninvasive Electrocardiol. 2009;14:65-71. doi: 10.1111/j.1542-474X.2008.00275.x.10.1111/j.1542-474X.2008.00275.x
- 19. Gertler MM, Garn SM, Levine SA. Serum uric acid in relation to age and physique in health and in coronary heart disease. Ann Intern Med. 1951;34:1421-1431. doi: 10.7326/0003-4819-34-6-1421.10.7326/0003-4819-34-6-1421
- 20. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA. 2000;283:2404-2410. doi: 10.1001/jama.283.18.2404.10.1001/jama.283.18.2404
- 21. Puddu PE, Lanti M, Menotti A, et al. Gubbio Study Research Group. Serum uric acid for short-term prediction of cardiovascular disease incidence in the Gubbio population study. Acta Cardiol. 2001;56:243-251. doi: 10.2143/AC.56.4.2005651.10.2143/AC.56.4.2005651
- 22. Franse LV, Pahor M, Di Bari M, et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). J Hypertens. 2000;18:1149-1154. doi: 10.1097/00004872-200018080-00021.10.1097/00004872-200018080-00021
- 23. Egas-Izquierdo M, Wong-Achi X, Alvarado-Villa G, et al. Relation between serum uric acid levels with the degree of coronary artery disease: A prospective study from Ecuador. Clin Investig Arterioscler. 2019;31:8-14. doi: 10.1016/j.arteri.2018.09.001.10.1016/j.arteri.2018.09.001
- 24. Kanbay M, Ikizek M, Solak Y, et al. Uric acid and pentraxin-3 levels are independently associated with coronary artery disease risk in patients with stage 2 and 3 kidney disease. Am J Nephrol. 2011;33:325-331. doi: 10.1159/000324916.10.1159/000324916
- 25. Moriarity JT, Folsom AR, Iribarren C, et al. Serum uric acid and risk of coronary heart disease: Atherosclerosis Risk in Communities (ARIC) Study. Ann Epidemiol. 2000;10:136-143. doi: 10.1016/s1047-2797(99)00037-x.10.1016/S1047-2797(99)00037-X
- 26. Culleton BF, Larson MG, Kannel WB, et al. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med. 1999;131:7-13. doi: 10.7326/0003-4819-131-1-199907060-00003.10.7326/0003-4819-131-1-199907060-00003
- 27. Wannamethee SG. Serum uric acid is not an independent risk factor for coronary heart disease. Curr Hypertens Rep. 2001;3:190-196. doi: 10.1007/s11906-001-0037-3.10.1007/s11906-001-0037-3
- 28. Sakata K, Hashimoto T, Ueshima H, et al. Absence of an association between serum uric acid and mortality from cardiovascular disease: NIPPON DATA 80, 1980-1994. Eur J Epidemiol. 2001;17:461-468. doi: 10.1023/a:1013735717961.10.1023/A:1013735717961
- 29. Naghavi M, John R, Naguib S, et al. pH Heterogeneity of human and rabbit atherosclerotic plaques; a new insight into detection of vulnerable plaque. Atherosclerosis. 2002;164:27-35. doi: 10.1016/s0021-9150(02)00018-7.10.1016/S0021-9150(02)00018-7
- 30. Hare JM, Johnson RJ. Uric acid predicts clinical outcomes in heart failure: insights regarding the role of xanthine oxidase and uric acid in disease pathophysiology. Circulation. 2003;107:1951-1953. doi: 10.1161/01.CIR.0000066420.36123.35.10.1161/01.CIR.0000066420.36123.35
- 31. Cappola TP, Kass DA, Nelson GS, et al. Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation. 2001;104:2407-2411. doi: 10.1161/hc4501.098928.10.1161/hc4501.098928
- 32. Farquharson CAJ, Butler R, Hill A, et al. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation. 2002;106:221-226. doi: 10.1161/01.cir.0000022140.61460.1d.10.1161/01.CIR.0000022140.61460.1D
- 33. Doehner W, Schoene N, Rauchhaus M, et al. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation. 2002;105:2619-2624. doi: 10.1161/01.cir.0000017502.58595.ed.10.1161/01.CIR.0000017502.58595.ED
- 34. Khosla UM, Zharikov S, Finch JL, et al. Hyperuricemia induces endothelial dysfunction. Kidney Int. 2005;67:1739-1742. doi: 10.1111/j.1523-1755.2005.00273.x.10.1111/j.1523-1755.2005.00273.x
- 35. Mazzali M, Kanellis J, Han L, et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol. 2002;282:F991-997. doi: 10.1152/ajprenal.00283.2001.10.1152/ajprenal.00283.2001
- 36. Mazalli M, Hughes J, Kim YG, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension. 2001;38:1101-1106. doi: 10.1161/hy1101.092839.10.1161/hy1101.092839
- 37. Waring WS, Adwani SH, Breukels O, et al. Hyperuricaemia does not impair cardiovascular function in healthy adults. Heart. 2004;90:155-159. doi: 10.1136/hrt.2003.016121.10.1136/hrt.2003.016121
- 38. Chamorro A, Planas AM. Yin and yang of uric acid in patients with stroke. Stroke. 2004;35:e11-e12. doi: 10.1161/01.STR.0000107762.79571.7D.10.1161/01.STR.0000107762.79571.7D
- 39. Cicero AF, Rosticci M, Tocci G, et al. Serum uric acid and other short-term predictors of electrocardiographic alterations in the Brisighella Heart Study cohort. Eur J Intern Med. 2015;26:255-258. doi: 10.1016/j.ejim.2015.02.007.10.1016/j.ejim.2015.02.007
- 40. Özyılmaz S, Satılmışoğlu MH, Gül M, et al. Evaluation of the association between serum uric acid level and the predicted risk score of sudden cardiac death in five years in patients with hypertrophic cardiomyopathy. Turk Kardiyol Dern Ars. 2018;46:111-120. doi: 10.5543/tkda.2017.60094.10.5543/tkda.2017.60094
- 41. Nodera M, Suzuki H, Matsumoto Y, et al. Association between Serum Uric Acid Level and Ventricular Tachyarrhythmia in Heart Failure Patients with Implantable Cardioverter-Defibrillator. Cardiology. 2018;140:47-51. doi: 10.1159/000488851.10.1159/000488851
- 42. Yamada S, Suzuki H, Kamioka M, et al. Uric acid increases the incidence of ventricular arrhythmia in patients with left ventricular hypertrophy. Fukushima J Med Sci. 2012;58:101-106. doi: 10.5387/fms.58.101.10.5387/fms.58.101